Kal Vista Pharmaceuticals, Inc. KALV
We take great care to ensure that the data presented and summarized in this overview for KalVista Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KALV
View all-
Vr Adviser, LLC New York, NY6.25MShares$75.4 Million6.36% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.19MShares$50.6 Million2.13% of portfolio
-
Tang Capital Management LLC San Diego, CA4.13MShares$49.8 Million5.96% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.69MShares$44.5 Million2.3% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.58MShares$31.1 Million0.06% of portfolio
-
Black Rock Inc. New York, NY2.43MShares$29.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.69MShares$20.3 Million0.0% of portfolio
-
Boxer Capital, LLC San Diego, CA1.59MShares$19.2 Million0.98% of portfolio
-
Capital World Investors Los Angeles, CA1.46MShares$17.7 Million0.0% of portfolio
-
Saturn V Capital Management LLC Austin, TX1.44MShares$17.4 Million6.86% of portfolio
Latest Institutional Activity in KALV
Top Purchases
Top Sells
About KALV
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Insider Transactions at KALV
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 20
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
28,288
-11.21%
|
$396,032
$14.29 P/Share
|
Feb 20
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
22,802
-10.85%
|
$319,228
$14.11 P/Share
|
Feb 20
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
12,053
-14.19%
|
$168,742
$14.11 P/Share
|
Feb 20
2024
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
24,888
-10.54%
|
$348,432
$14.11 P/Share
|
Feb 20
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
14,295
-21.28%
|
$200,130
$14.12 P/Share
|
Feb 17
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,788
+17.2%
|
-
|
Feb 17
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
51,029
+19.54%
|
-
|
Feb 17
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,788
+18.11%
|
-
|
Feb 17
2024
|
Thomas Andrew Crockett CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
54,415
+18.73%
|
-
|
Feb 17
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,613
+31.3%
|
-
|
Feb 14
2024
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
58,356
-24.31%
|
$875,340
$15.01 P/Share
|
Feb 14
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
40,855
-20.43%
|
$612,825
$15.01 P/Share
|
Feb 14
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
39,886
-37.61%
|
$598,290
$15.01 P/Share
|
Feb 14
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
28,171
-28.22%
|
$422,565
$15.01 P/Share
|
Feb 11
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+37.54%
|
-
|
Feb 11
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+30.44%
|
-
|
Feb 11
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+36.13%
|
-
|
Feb 11
2024
|
Thomas Andrew Crockett CEO |
BUY
Grant, award, or other acquisition
|
Direct |
122,500
+33.79%
|
-
|
Feb 08
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
29,747
+0.61%
|
$416,458
$14.7 P/Share
|
Feb 07
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
51,827
+1.07%
|
$725,578
$14.56 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 439K shares |
---|---|
Grant, award, or other acquisition | 330K shares |
Open market or private purchase | 1.25M shares |
Open market or private sale | 480K shares |
---|---|
Bona fide gift | 8K shares |